Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.

Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $3.5 billion in sales in 2022, after posting a mixed fourth-quarter report that slightly beat on earnings estimates but missed on revenue.

Imagine getting a positive result on a genetic test. The doctor tells you that you have a “pathogenic genetic variant,” or a DNA sequence that is known to raise the chances for getting a disease like breast cancer or diabetes.

Gene editing company Metagenomi said on Tuesday that it has raised $175 million in a Series B financing round, bringing the total funding for the Emeryville, California-based startup to $300 million.

Shenzhen, China, January 24, 2022: Medcaptain Medical Technology and Penlon, a world-renowned medical device manufacturer, formally entered into an acquisition.

Recently, Novogene released the finance forecast that the net profit attributable to owners of the parent company in 2021 was 190 million to 228 million yuan, a year-on-year increase of 419.99% to 523.99%.

Illumina said on Monday that it is collaborating with National Cancer Center Japan on a study of nasopharyngeal carcinoma.

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant’s high rate of infection.

Pancreatic cancer is a rare, yet elusive and deadly cancer, with a five-year survival rate of about 10%. If the cancer has metastasized, that rate lowers to 3%. And treatment options are extremely limited.